UnitedHealth Group (UNH) Stock
Company Profile
Price: $580.65
Market Cap: $536.18B
Exchange: NYSE
CEO: Sir Andrew Philip Witty
Sector: Healthcare
Industry: Medical - Healthcare Plans
Employees: 440.00K
Headquarters: Minnetonka, MN
Website: UnitedHealth Group
Business Summary
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage and well-being services to individuals age 50 and older addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance and health care programs; health and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
UnitedHealth Group Chart
UnitedHealth Group News
UnitedHealth: We See Significant Long-Term Upside
UnitedHealth was our top pick for 2024 due to its strong operating plan and attractive valuation. Despite trailing the S&P 500 by 11%, the stock's long-term potential remains as industry headwinds, like Medicaid and Medicare slowdowns, ease into 2025. UNH's large size and data advantages enable cost-savings and better patient outcomes, making it a strong investment amid rising competitive pressures and regulatory scrutiny.
-
seekingalpha.com
2024-09-17
UnitedHealth Group: Cyberattack Is Manageable, Initiate With A 'Strong Buy'
UnitedHealth's aggressive M&A strategy, including the $13 billion acquisition of Change Healthcare, has strengthened its data analytics and improved margins, justifying a 'Strong Buy' rating. Despite a major cyberattack, UnitedHealth's financial impact is manageable, with expected EPS reduction and increased CAPEX for cybersecurity enhancements. UnitedHealth's divestiture of its Brazilian business reduces FX risk, aligning with its focus on U.S. market growth driven by rising healthcare spending.
-
seekingalpha.com
2024-09-13
UnitedHealth Group: Reaches Near All-Time High But Still Looks Like A 'Buy' (Rating Upgrade)
UnitedHealth Group remains a solid buy-and-hold type of stock for the long-term dividend growth investor. Shares have recently touched a new all-time high; despite that, based on earnings growth going forward, the share price doesn't look overvalued here. Consistent earnings beats could suggest that the shares are also on the cheaper end based on the fair value range, with a chance for double-digit dividend growth to continue.
-
seekingalpha.com
2024-09-12
3 Dividend Growth Stocks That Raised Their Payouts by 400%-Plus in 10 Years
Dividend stocks that aggressively grow their payouts can be more valuable than income stocks with long growth streaks. Companies with resilient operations and strong growth prospects can make for excellent long-term investments.
-
fool.com
2024-09-11
UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year
UnitedHealth Group said on Tuesday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and recommend less expensive biosimilar versions of the medicine instead.
-
reuters.com
2024-09-10
UnitedHealth Group Earnings
This section highlight's UnitedHealth Group's earnings, including earnings call transcripts, earnings surprises, and key dates.
UnitedHealth Group Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q2 | 2024 | 2024-07-16 | $6.65 | $6.80 |
| Read Transcript | Q1 | 2024 | 2024-04-16 | $6.61 | $6.91 |
| Read Transcript | Q4 | 2023 | 2024-01-12 | $5.98 | $6.16 |
| Read Transcript | Q3 | 2023 | 2023-10-13 | $6.32 | $6.56 |
| Read Transcript | Q2 | 2023 | 2023-07-14 | $5.99 | $6.14 |
| Read Transcript | Q1 | 2023 | 2023-04-14 | $6.13 | $6.26 |
| Read Transcript | Q4 | 2022 | 2023-01-13 | $5.17 | $5.34 |
| Read Transcript | Q3 | 2022 | 2022-10-14 | $5.42 | $5.79 |
| Read Transcript | Q2 | 2022 | 2022-07-15 | $5.20 | $5.57 |
| Read Transcript | Q1 | 2022 | 2022-04-14 | $5.38 | $5.49 |
UnitedHealth Group Earnings Dates
When is the next earnings date for UNH?
Date: 2024-10-15Status: Unconfirmed
Time of Day: Before Market
Estimated EPS: $7.05
When was the last earnings date for UNH?
Date: 2024-07-16Fiscal Date Ending: 2024-06-30
EPS: $6.80
Estimated EPS: $6.65
Revenue: $97.86B
Estimated Revenue: $98.79B
Upcoming UNH Earnings
| Date | Estimated EPS | Time of Day | Status |
|---|---|---|---|
| 2024-10-15 | $7.05 | Before Market | Unconfirmed |
| 2025-01-10 | N/A | Before Market | Unconfirmed |
| 2025-04-14 | N/A | Before Market | Unconfirmed |
| 2025-07-14 | N/A | Before Market | Unconfirmed |
Financial Statements
This section provides financial statements for UnitedHealth Groupincluding income statements, balance sheets, and cash flow statements, both annually and quarterly.
Annual Income Statement
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Revenue | $242.16B | $255.64B | $285.27B | $322.13B | $367.53B |
| Cost of Revenue | $184.56B | $190.14B | $217.94B | $244.54B | $280.66B |
| Gross Profit | $57.60B | $65.50B | $67.33B | $77.59B | $86.87B |
| Gross Profit Ratio | 23.79% | 25.62% | 23.60% | 24.09% | 23.64% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $35.19B | $41.70B | $42.58B | $47.78B | $54.63B |
| Other Expenses | $2.72B | $2.89B | $3.10B | $3.40B | $3.97B |
| Operating Expenses | $37.91B | $44.59B | $45.68B | $51.18B | $58.60B |
| Cost and Expenses | $222.47B | $234.74B | $263.63B | $295.73B | $339.26B |
| Interest Income | $- | $- | $- | $- | $- |
| Interest Expense | $1.70B | $1.66B | $1.66B | $2.09B | $3.25B |
| Depreciation and Amortization | $2.72B | $2.89B | $3.10B | $3.40B | $3.97B |
| EBITDA | $22.41B | $23.79B | $24.75B | $29.80B | $32.24B |
| EBITDA Ratio | 9.25% | 9.31% | 8.68% | 9.25% | 8.77% |
| Operating Income | $19.68B | $22.41B | $23.97B | $28.43B | $32.36B |
| Operating Income Ratio | 8.13% | 8.76% | 8.40% | 8.83% | 8.80% |
| Total Other Income Expenses Net | $1.89B | $1.50B | $2.32B | $2.03B | $4.09B |
| Income Before Tax | $17.98B | $20.74B | $22.31B | $26.34B | $29.11B |
| Income Before Tax Ratio | 7.43% | 8.11% | 7.82% | 8.18% | 7.92% |
| Income Tax Expense | $3.74B | $4.97B | $4.58B | $5.70B | $5.97B |
| Net Income | $13.84B | $15.40B | $17.29B | $20.12B | $22.38B |
| Net Income Ratio | 5.71% | 6.03% | 6.06% | 6.25% | 6.09% |
| EPS | $14.55 | $16.28 | $18.33 | $21.54 | $24.12 |
| EPS Diluted | $14.33 | $16.03 | $18.08 | $21.18 | $23.86 |
| Weighted Average Shares Outstanding | 951.00M | 946.00M | 943.00M | 934.00M | 928.00M |
| Weighted Average Shares Outstanding Diluted | 966.00M | 961.00M | 956.00M | 950.00M | 938.00M |
| SEC Filing | Source | Source | Source | Source | Source |
Quarterly Income Statement
| Breakdown | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $60.35B | $60.90B | $64.42B | $62.14B | $65.11B | $65.47B | $70.20B | $71.32B | $72.34B | $73.74B | $80.15B | $80.33B | $80.89B | $82.79B | $91.13B | $91.79B | $91.36B | $93.25B | $98.78B | $97.86B |
| Cost of Revenue | $45.67B | $45.79B | $48.69B | $42.18B | $49.57B | $49.70B | $52.48B | $54.21B | $55.10B | $56.16B | $61.01B | $60.69B | $60.94B | $61.91B | $69.25B | $70.02B | $68.97B | $72.42B | $76.79B | $76.80B |
| Gross Profit | $14.68B | $15.11B | $15.73B | $19.96B | $15.54B | $15.76B | $17.72B | $17.11B | $17.23B | $17.58B | $19.14B | $19.64B | $19.95B | $20.88B | $21.88B | $21.77B | $22.39B | $20.82B | $21.99B | $21.06B |
| Gross Profit Ratio | 24.33% | 24.82% | 24.42% | 32.12% | 23.87% | 24.08% | 25.24% | 24.00% | 23.82% | 23.84% | 23.88% | 24.45% | 24.67% | 25.22% | 24.01% | 23.72% | 24.51% | 22.33% | 22.26% | 21.52% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $8.96B | $9.30B | $10.02B | $10.00B | $10.17B | $11.51B | $10.22B | $10.36B | $10.72B | $11.27B | $11.40B | $11.71B | $11.66B | $13.01B | $13.62B | $13.81B | $13.86B | $13.34B | $14.08B | $13.16B |
| Other Expenses | $709.00M | $718.00M | $723.00M | $717.00M | $719.00M | $732.00M | $758.00M | $778.00M | $796.00M | $771.00M | $788.00M | $802.00M | $828.00M | $982.00M | $970.00M | $1.02B | $1.01B | $974.00M | $997.00M | $1.02B |
| Operating Expenses | $9.67B | $10.02B | $10.74B | $10.72B | $10.89B | $12.25B | $10.98B | $11.14B | $11.52B | $12.04B | $12.19B | $12.51B | $12.49B | $13.99B | $14.60B | $14.83B | $14.86B | $14.31B | $15.07B | $14.18B |
| Cost and Expenses | $55.34B | $55.81B | $59.42B | $52.90B | $60.46B | $61.95B | $63.46B | $65.34B | $66.62B | $68.20B | $73.20B | $73.20B | $73.43B | $75.90B | $83.84B | $84.85B | $83.83B | $86.74B | $91.86B | $90.98B |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $449.00M | $437.00M | $437.00M | $430.00M | $395.00M | $401.00M | $397.00M | $410.00M | $422.00M | $431.00M | $433.00M | $467.00M | $516.00M | $676.00M | $754.00M | $828.00M | $834.00M | $830.00M | $844.00M | $985.00M |
| Depreciation and Amortization | $709.00M | $718.00M | $723.00M | $717.00M | $719.00M | $732.00M | $758.00M | $778.00M | $796.00M | $771.00M | $788.00M | $802.00M | $828.00M | $982.00M | $970.00M | $1.02B | $1.01B | $974.00M | $997.00M | $1.02B |
| EBITDA | $5.72B | $5.81B | $5.72B | $9.96B | $5.37B | $4.25B | $7.50B | $6.76B | $6.51B | $6.31B | $7.74B | $7.93B | $8.29B | $7.87B | $8.26B | $7.96B | $8.54B | $7.48B | $7.92B | $7.90B |
| EBITDA Ratio | 9.48% | 9.54% | 8.88% | 16.03% | 8.25% | 6.49% | 10.68% | 9.47% | 9.00% | 8.56% | 9.65% | 9.88% | 10.25% | 9.51% | 9.06% | 8.68% | 9.34% | 8.03% | 8.01% | 8.07% |
| Operating Income | $5.01B | $5.09B | $5.00B | $9.24B | $4.65B | $3.52B | $6.74B | $5.98B | $5.71B | $5.54B | $6.95B | $7.13B | $7.46B | $6.89B | $8.09B | $8.06B | $8.53B | $7.69B | $7.93B | $7.88B |
| Operating Income Ratio | 8.31% | 8.37% | 7.76% | 14.87% | 7.14% | 5.37% | 9.60% | 8.38% | 7.90% | 7.51% | 8.67% | 8.88% | 9.22% | 8.32% | 8.87% | 8.78% | 9.33% | 8.25% | 8.03% | 8.05% |
| Total Other Income Expenses Net | $466.00M | $433.00M | $365.00M | $341.00M | $351.00M | $445.00M | $452.00M | $556.00M | $503.00M | $813.00M | $367.00M | $295.00M | $513.00M | $855.00M | $798.00M | $1.11B | $997.00M | $1.18B | $-6.08B | $-228.00M |
| Income Before Tax | $4.57B | $4.66B | $4.56B | $8.81B | $4.26B | $3.12B | $6.34B | $5.57B | $5.29B | $5.11B | $6.52B | $6.67B | $6.95B | $6.21B | $7.33B | $7.23B | $7.69B | $6.86B | $1.00M | $5.67B |
| Income Before Tax Ratio | 7.56% | 7.65% | 7.08% | 14.18% | 6.54% | 4.76% | 9.03% | 7.81% | 7.31% | 6.93% | 8.13% | 8.30% | 8.59% | 7.51% | 8.05% | 7.88% | 8.42% | 7.36% | 0.00% | 5.79% |
| Income Tax Expense | $936.00M | $990.00M | $1.09B | $2.12B | $1.00B | $764.00M | $1.36B | $1.20B | $1.10B | $919.00M | $1.37B | $1.47B | $1.56B | $1.31B | $1.56B | $1.57B | $1.65B | $1.18B | $1.22B | $1.24B |
| Net Income | $3.54B | $3.54B | $3.38B | $6.64B | $3.17B | $2.21B | $4.86B | $4.27B | $4.09B | $4.07B | $5.03B | $5.07B | $5.26B | $4.76B | $5.61B | $5.47B | $5.84B | $5.46B | $-1.41B | $4.22B |
| Net Income Ratio | 5.86% | 5.81% | 5.25% | 10.68% | 4.87% | 3.38% | 6.93% | 5.98% | 5.65% | 5.52% | 6.27% | 6.31% | 6.50% | 5.75% | 6.16% | 5.96% | 6.39% | 5.85% | -1.43% | 4.31% |
| EPS | $3.74 | $3.74 | $3.57 | $6.99 | $3.34 | $2.34 | $5.15 | $4.52 | $4.34 | $4.33 | $5.35 | $5.42 | $5.63 | $5.10 | $6.01 | $5.89 | $6.31 | $5.90 | $-1.53 | $4.58 |
| EPS Diluted | $3.67 | $3.68 | $3.52 | $6.91 | $3.30 | $2.30 | $5.08 | $4.46 | $4.28 | $4.26 | $5.27 | $5.34 | $5.55 | $5.03 | $5.95 | $5.82 | $6.24 | $5.83 | $-1.53 | $4.54 |
| Weighted Average Shares Outstanding | 947.00M | 948.00M | 947.00M | 950.00M | 949.00M | 946.00M | 944.00M | 943.00M | 942.00M | 941.00M | 939.00M | 935.00M | 935.00M | 934.00M | 933.00M | 930.00M | 926.00M | 924.00M | 920.00M | 921.00M |
| Weighted Average Shares Outstanding Diluted | 963.00M | 962.00M | 962.00M | 960.00M | 962.00M | 961.00M | 957.00M | 956.00M | 955.00M | 955.00M | 954.00M | 950.00M | 948.00M | 947.00M | 943.00M | 940.00M | 936.00M | 935.00M | 922.00M | 928.00M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $10.98B | $16.92B | $21.38B | $23.36B | $25.43B |
| Short Term Investments | $3.26B | $2.86B | $2.53B | $4.55B | $4.20B |
| Cash and Short Term Investments | $14.24B | $19.78B | $23.91B | $27.91B | $29.63B |
| Net Receivables | $11.82B | $12.87B | $14.22B | $17.68B | $38.97B |
| Inventory | $- | $- | $- | $- | $-68.60B |
| Other Current Assets | $16.57B | $21.07B | $23.64B | $23.48B | $78.44B |
| Total Current Assets | $42.63B | $53.72B | $61.76B | $69.07B | $78.44B |
| Property Plant Equipment Net | $8.70B | $8.63B | $8.97B | $10.13B | $11.45B |
| Goodwill | $65.66B | $71.34B | $75.80B | $93.35B | $103.73B |
| Intangible Assets | $10.35B | $10.86B | $10.04B | $14.40B | $15.19B |
| Goodwill and Intangible Assets | $76.01B | $82.19B | $85.84B | $107.75B | $118.93B |
| Long Term Investments | $37.21B | $41.24B | $43.11B | $43.73B | $47.61B |
| Tax Assets | $-84.71B | $-90.82B | $-94.81B | $2.77B | $4.70B |
| Other Non-Current Assets | $94.05B | $102.33B | $107.33B | $12.26B | $17.30B |
| Total Non-Current Assets | $131.25B | $143.57B | $150.45B | $176.64B | $199.98B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $173.89B | $197.29B | $212.21B | $245.71B | $278.42B |
| Account Payables | $21.69B | $21.87B | $24.48B | $29.06B | $31.96B |
| Short Term Debt | $3.87B | $4.82B | $3.62B | $3.11B | $5.31B |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $2.62B | $2.84B | $2.57B | $3.08B | $3.35B |
| Other Current Liabilities | $33.60B | $42.89B | $47.62B | $54.00B | $58.43B |
| Total Current Liabilities | $61.78B | $72.42B | $78.29B | $89.24B | $99.05B |
| Long Term Debt | $36.81B | $38.65B | $42.38B | $54.51B | $58.26B |
| Deferred Revenue Non-Current | $-2.99B | $-3.37B | $-3.27B | $2.77B | $3.35B |
| Deferred Tax Liabilities Non-Current | $2.99B | $3.37B | $3.27B | $2.77B | $7.72B |
| Other Non-Current Liabilities | $13.14B | $15.68B | $15.05B | $10.07B | $11.11B |
| Total Non-Current Liabilities | $49.95B | $54.33B | $57.44B | $70.12B | $80.44B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $111.73B | $126.75B | $135.73B | $159.36B | $179.50B |
| Preferred Stock | $2.81B | $- | $- | $- | $- |
| Common Stock | $9.00M | $10.00M | $10.00M | $9.00M | $9.00M |
| Retained Earnings | $61.18B | $69.30B | $77.13B | $86.16B | $95.77B |
| Accumulated Other Comprehensive Income Loss | $-3.58B | $-3.81B | $-5.38B | $-8.39B | $-7.03B |
| Other Total Stockholders Equity | $16.00M | $- | $- | $- | $- |
| Total Stockholders Equity | $60.44B | $65.49B | $71.76B | $77.77B | $88.76B |
| Total Equity | $62.16B | $70.54B | $76.48B | $86.35B | $98.92B |
| Total Liabilities and Stockholders Equity | $173.89B | $197.29B | $212.21B | $245.71B | $273.72B |
| Minority Interest | $1.73B | $5.05B | $4.72B | $8.57B | $10.16B |
| Total Liabilities and Total Equity | $173.89B | $197.29B | $212.21B | $245.71B | $273.72B |
| Total Investments | $40.47B | $44.10B | $45.65B | $71.64B | $4.20B |
| Total Debt | $40.68B | $43.47B | $46.00B | $57.62B | $67.44B |
| Net Debt | $29.69B | $26.55B | $24.63B | $34.26B | $42.01B |
Quarterly Balance Sheet
| Breakdown | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $12.36B | $10.98B | $21.57B | $22.33B | $17.55B | $16.92B | $19.95B | $19.83B | $21.09B | $21.38B | $25.48B | $24.61B | $38.84B | $23.36B | $46.50B | $46.28B | $38.91B | $25.43B | $28.41B | $26.29B |
| Short Term Investments | $3.46B | $3.26B | $2.88B | $3.27B | $3.26B | $2.86B | $2.96B | $2.73B | $2.79B | $2.53B | $2.91B | $3.35B | $3.68B | $4.55B | $46.50B | $46.28B | $5.18B | $4.20B | $4.30B | $5.04B |
| Cash and Short Term Investments | $15.82B | $14.24B | $24.45B | $25.59B | $20.81B | $19.78B | $22.92B | $22.56B | $23.87B | $23.91B | $28.40B | $27.96B | $42.53B | $27.91B | $46.50B | $46.28B | $44.10B | $29.63B | $32.71B | $31.32B |
| Net Receivables | $10.96B | $11.82B | $14.61B | $12.55B | $12.17B | $12.87B | $15.98B | $14.59B | $14.15B | $14.22B | $18.87B | $31.16B | $17.05B | $17.68B | $22.41B | $17.95B | $20.67B | $38.97B | $46.48B | $49.88B |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-68.60B | $-74.89B | $- |
| Other Current Assets | $16.76B | $16.57B | $19.75B | $20.78B | $21.84B | $21.07B | $20.61B | $21.77B | $23.59B | $23.64B | $21.76B | $9.23B | $23.36B | $23.48B | $24.98B | $25.64B | $27.14B | $78.44B | $88.94B | $10.84B |
| Total Current Assets | $43.54B | $42.63B | $58.81B | $58.92B | $54.82B | $53.72B | $59.51B | $58.92B | $61.61B | $61.76B | $69.03B | $68.36B | $82.94B | $69.07B | $93.89B | $89.87B | $91.91B | $78.44B | $88.94B | $92.04B |
| Property Plant Equipment Net | $8.50B | $8.70B | $8.17B | $8.13B | $8.15B | $8.63B | $8.50B | $8.73B | $8.73B | $8.97B | $9.18B | $9.42B | $9.47B | $10.13B | $10.64B | $10.93B | $11.07B | $11.45B | $10.43B | $9.80B |
| Goodwill | $65.20B | $65.66B | $65.30B | $67.87B | $68.09B | $71.34B | $72.16B | $75.83B | $75.44B | $75.80B | $77.55B | $84.16B | $83.90B | $93.35B | $100.41B | $101.67B | $101.70B | $103.73B | $105.66B | $105.44B |
| Intangible Assets | $10.52B | $10.35B | $10.20B | $10.55B | $10.37B | $10.86B | $10.84B | $10.81B | $10.44B | $10.04B | $9.92B | $11.29B | $10.79B | $14.40B | $16.16B | $15.64B | $15.20B | $15.19B | $15.54B | $14.73B |
| Goodwill and Intangible Assets | $75.73B | $76.01B | $75.50B | $78.42B | $78.46B | $82.19B | $83.00B | $86.63B | $85.87B | $85.84B | $87.47B | $95.44B | $94.69B | $107.75B | $116.57B | $117.31B | $116.90B | $118.93B | $121.21B | $120.17B |
| Long Term Investments | $36.84B | $37.21B | $36.58B | $36.78B | $39.18B | $41.24B | $42.41B | $44.06B | $44.78B | $43.11B | $42.35B | $42.43B | $41.56B | $43.73B | $46.88B | $45.99B | $45.47B | $47.61B | $5.50B | $46.11B |
| Tax Assets | $2.90B | $-84.71B | $3.03B | $3.29B | $3.34B | $-90.82B | $3.60B | $3.64B | $3.65B | $-94.81B | $2.95B | $2.58B | $1.66B | $4.60B | $2.83B | $2.50B | $2.21B | $4.70B | $4.17B | $3.63B |
| Other Non-Current Assets | $6.20B | $94.05B | $6.98B | $6.95B | $7.01B | $102.33B | $8.15B | $8.31B | $8.41B | $107.33B | $10.25B | $11.94B | $12.75B | $10.43B | $12.86B | $13.57B | $14.50B | $17.30B | $53.96B | $14.31B |
| Total Non-Current Assets | $130.17B | $131.25B | $130.26B | $133.56B | $136.15B | $143.57B | $145.66B | $151.38B | $151.44B | $150.45B | $152.21B | $161.82B | $160.13B | $176.64B | $189.78B | $190.29B | $190.16B | $199.98B | $195.27B | $194.02B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $173.71B | $173.89B | $189.07B | $192.48B | $190.97B | $197.29B | $205.17B | $210.29B | $213.04B | $212.21B | $221.24B | $230.17B | $243.06B | $245.71B | $283.68B | $280.16B | $282.06B | $278.42B | $284.21B | $286.06B |
| Account Payables | $20.94B | $21.69B | $22.77B | $19.20B | $21.17B | $21.87B | $24.83B | $25.13B | $25.92B | $24.48B | $28.68B | $54.12B | $29.06B | $29.06B | $31.81B | $31.95B | $32.79B | $31.96B | $30.74B | $30.89B |
| Short Term Debt | $6.39B | $3.87B | $15.83B | $6.16B | $3.90B | $4.82B | $8.84B | $3.87B | $3.62B | $3.62B | $6.70B | $5.59B | $3.23B | $3.11B | $9.93B | $6.32B | $5.29B | $5.31B | $9.79B | $11.37B |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $2.50B | $2.62B | $2.51B | $2.30B | $2.39B | $2.84B | $2.61B | $2.37B | $2.56B | $2.57B | $2.67B | $2.21B | $12.85B | $3.08B | $14.49B | $14.85B | $15.31B | $3.35B | $3.21B | $2.57B |
| Other Current Liabilities | $32.81B | $33.60B | $37.50B | $42.23B | $39.14B | $42.89B | $44.36B | $45.19B | $47.48B | $47.62B | $50.12B | $26.77B | $55.80B | $54.00B | $60.26B | $59.86B | $60.79B | $58.43B | $60.70B | $59.84B |
| Total Current Liabilities | $62.64B | $61.78B | $78.61B | $69.88B | $66.60B | $72.42B | $80.64B | $76.56B | $79.58B | $78.29B | $88.17B | $88.70B | $100.94B | $89.24B | $116.48B | $112.98B | $114.18B | $99.05B | $104.43B | $104.67B |
| Long Term Debt | $38.51B | $36.81B | $35.78B | $39.90B | $39.90B | $38.65B | $37.42B | $44.35B | $43.34B | $42.38B | $40.80B | $45.80B | $45.44B | $54.51B | $60.66B | $59.27B | $58.08B | $58.26B | $63.85B | $63.73B |
| Deferred Revenue Non-Current | $-2.90B | $2.99B | $-3.03B | $-3.29B | $-3.34B | $3.37B | $-3.60B | $-3.64B | $-3.65B | $3.27B | $2.67B | $2.21B | $1.66B | $2.77B | $14.49B | $-2.50B | $-2.21B | $3.35B | $3.21B | $-18.43B |
| Deferred Tax Liabilities Non-Current | $2.90B | $2.99B | $3.03B | $3.29B | $3.34B | $3.37B | $3.60B | $3.64B | $3.65B | $3.27B | $2.95B | $2.58B | $1.66B | $2.77B | $2.83B | $2.50B | $2.21B | $7.72B | $4.17B | $3.63B |
| Other Non-Current Liabilities | $12.81B | $7.15B | $13.08B | $14.34B | $14.53B | $8.95B | $16.53B | $16.07B | $15.49B | $8.52B | $9.00B | $9.76B | $10.45B | $10.07B | $-1.40B | $15.76B | $15.82B | $11.11B | $11.64B | $14.79B |
| Total Non-Current Liabilities | $51.32B | $49.95B | $48.86B | $54.24B | $54.42B | $54.33B | $53.95B | $60.41B | $58.84B | $57.44B | $55.42B | $60.35B | $59.21B | $70.12B | $76.58B | $75.03B | $73.90B | $80.44B | $82.86B | $63.73B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $18.43B |
| Total Liabilities | $113.96B | $111.73B | $127.46B | $124.13B | $121.02B | $126.75B | $134.59B | $136.97B | $138.41B | $135.73B | $143.59B | $149.04B | $160.14B | $159.36B | $193.06B | $188.01B | $188.08B | $179.50B | $187.29B | $186.82B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $9.00M | $9.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $10.00M | $9.00M | $9.00M | $9.00M | $9.00M | $9.00M | $9.00M | $9.00M |
| Retained Earnings | $58.70B | $61.18B | $62.33B | $67.78B | $69.72B | $69.30B | $71.22B | $73.09B | $75.12B | $77.13B | $78.78B | $80.54B | $83.72B | $86.16B | $88.85B | $89.99B | $93.17B | $95.77B | $90.12B | $92.40B |
| Accumulated Other Comprehensive Income Loss | $-3.71B | $-3.58B | $-5.36B | $-4.55B | $-4.49B | $-3.81B | $-4.83B | $-4.09B | $-4.86B | $-5.38B | $-6.03B | $-7.73B | $-9.09B | $-8.39B | $-7.55B | $-7.65B | $-8.69B | $-7.03B | $-3.44B | $-3.42B |
| Other Total Stockholders Equity | $- | $7.00M | $- | $388.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-4.18B |
| Total Stockholders Equity | $55.00B | $57.62B | $56.98B | $63.62B | $65.23B | $65.49B | $66.40B | $69.01B | $70.28B | $71.76B | $72.77B | $72.82B | $74.65B | $77.77B | $81.31B | $82.35B | $84.49B | $88.76B | $86.69B | $84.80B |
| Total Equity | $59.75B | $62.16B | $61.60B | $68.36B | $69.95B | $70.54B | $70.58B | $73.32B | $74.63B | $76.48B | $77.65B | $81.13B | $82.92B | $86.35B | $90.62B | $92.16B | $93.98B | $98.92B | $96.92B | $94.68B |
| Total Liabilities and Stockholders Equity | $173.71B | $173.89B | $189.07B | $192.48B | $190.97B | $197.29B | $205.17B | $210.29B | $213.04B | $212.21B | $221.24B | $230.17B | $243.06B | $245.71B | $283.68B | $280.16B | $282.06B | $273.72B | $284.21B | $286.06B |
| Minority Interest | $4.75B | $4.55B | $4.63B | $4.73B | $4.72B | $5.05B | $4.18B | $4.31B | $4.35B | $4.72B | $4.88B | $8.31B | $8.28B | $8.57B | $9.31B | $9.80B | $9.49B | $10.16B | $10.23B | $9.88B |
| Total Liabilities and Total Equity | $173.71B | $173.89B | $189.07B | $192.48B | $190.97B | $197.29B | $205.17B | $210.29B | $213.04B | $212.21B | $221.24B | $230.17B | $243.06B | $245.71B | $283.68B | $280.16B | $282.06B | $273.72B | $284.21B | $286.06B |
| Total Investments | $40.30B | $40.47B | $39.45B | $40.04B | $42.44B | $44.10B | $45.37B | $46.79B | $47.56B | $45.65B | $45.27B | $45.78B | $45.24B | $71.64B | $93.38B | $45.99B | $45.47B | $4.20B | $9.80B | $51.15B |
| Total Debt | $44.89B | $40.68B | $51.61B | $46.06B | $43.79B | $43.47B | $46.26B | $48.22B | $46.97B | $46.00B | $47.49B | $51.39B | $48.67B | $57.62B | $70.59B | $65.59B | $63.37B | $67.44B | $73.64B | $75.10B |
| Net Debt | $32.53B | $29.69B | $30.04B | $23.73B | $26.24B | $26.55B | $26.30B | $28.38B | $25.88B | $24.63B | $22.01B | $26.78B | $9.82B | $34.26B | $24.09B | $19.31B | $24.45B | $42.01B | $45.22B | $48.81B |
Annual Cash Flow Statement
| Breakdown | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Net Income | $14.24B | $15.77B | $17.73B | $20.64B | $22.38B |
| Depreciation and Amortization | $2.72B | $2.89B | $3.10B | $3.40B | $3.97B |
| Deferred Income Tax | $124.00M | $-60.00M | $-814.00M | $-1.00B | $-245.00M |
| Stock Based Compensation | $697.00M | $679.00M | $800.00M | $925.00M | $1.06B |
| Change in Working Capital | $683.00M | $2.90B | $1.52B | $2.25B | $1.64B |
| Accounts Receivables | $162.00M | $-688.00M | $-1.00B | $-2.52B | $-3.11B |
| Inventory | $-1.56B | $-2.19B | $-1.03B | $- | $1.04B |
| Accounts Payables | $1.95B | $5.50B | $3.86B | $1.96B | $3.52B |
| Other Working Capital | $130.00M | $278.00M | $-310.00M | $2.81B | $203.00M |
| Other Non Cash Items | $6.66B | $6.77B | $6.64B | $7.24B | $258.00M |
| Net Cash Provided by Operating Activities | $18.46B | $22.17B | $22.34B | $26.21B | $29.07B |
| Investments in Property Plant and Equipment | $-2.07B | $-2.05B | $-2.45B | $-2.80B | $-3.39B |
| Acquisitions Net | $-8.34B | $-7.14B | $-4.82B | $-21.46B | $-10.18B |
| Purchases of Investments | $-2.50B | $-2.84B | $-1.84B | $-6.84B | $-18.31B |
| Sales Maturities of Investments | $15.63B | $13.74B | $15.30B | $11.99B | $16.54B |
| Other Investing Activities | $-15.41B | $-14.25B | $-16.55B | $-9.37B | $-960.00M |
| Net Cash Used for Investing Activities | $-12.70B | $-12.53B | $-10.37B | $-28.48B | $-16.30B |
| Debt Repayment | $-1.75B | $-3.15B | $-3.15B | $-3.02B | $-4.28B |
| Common Stock Issued | $1.04B | $1.44B | $1.35B | $1.25B | $1.35B |
| Common Stock Repurchased | $-5.50B | $-4.25B | $-5.00B | $-7.00B | $-8.00B |
| Dividends Paid | $-3.93B | $-4.58B | $-5.28B | $-5.99B | $-6.76B |
| Other Financing Activities | $4.52B | $6.95B | $4.62B | $18.98B | $6.89B |
| Net Cash Used Provided by Financing Activities | $-5.62B | $-3.59B | $-7.46B | $4.23B | $-10.80B |
| Effect of Forex Changes on Cash | $-20.00M | $-116.00M | $-62.00M | $34.00M | $97.00M |
| Net Change in Cash | $119.00M | $5.94B | $4.45B | $1.99B | $2.06B |
| Cash at End of Period | $10.98B | $16.92B | $21.38B | $23.36B | $25.43B |
| Cash at Beginning of Period | $10.87B | $10.98B | $16.92B | $21.38B | $23.36B |
| Operating Cash Flow | $18.46B | $22.17B | $22.34B | $26.21B | $29.07B |
| Capital Expenditure | $-2.07B | $-2.05B | $-2.45B | $-2.80B | $-3.39B |
| Free Cash Flow | $16.39B | $20.12B | $19.89B | $23.40B | $25.68B |
Quarterly Cash Flow Statement
| Breakdown | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $3.63B | $3.67B | $3.46B | $6.70B | $3.26B | $2.35B | $4.98B | $4.37B | $4.19B | $4.19B | $5.15B | $5.20B | $5.38B | $4.91B | $5.77B | $5.66B | $6.04B | $5.46B | $-1.41B | $4.22B |
| Depreciation and Amortization | $709.00M | $718.00M | $723.00M | $717.00M | $719.00M | $732.00M | $758.00M | $778.00M | $796.00M | $771.00M | $788.00M | $802.00M | $828.00M | $982.00M | $970.00M | $1.02B | $1.01B | $974.00M | $997.00M | $1.02B |
| Deferred Income Tax | $-72.00M | $128.00M | $247.00M | $-9.00M | $-71.00M | $-227.00M | $286.00M | $-173.00M | $65.00M | $-992.00M | $178.00M | $-176.00M | $-790.00M | $-414.00M | $-263.00M | $-241.00M | $-71.00M | $249.00M | $-27.00M | $-331.00M |
| Stock Based Compensation | $127.00M | $172.00M | $231.00M | $157.00M | $139.00M | $152.00M | $256.00M | $170.00M | $165.00M | $209.00M | $299.00M | $205.00M | $171.00M | $250.00M | $362.00M | $242.00M | $247.00M | $208.00M | $372.00M | $222.00M |
| Change in Working Capital | $-1.24B | $1.52B | $-1.72B | $2.44B | $-916.00M | $3.09B | $-273.00M | $393.00M | $2.36B | $-961.00M | $-1.09B | $643.00M | $12.96B | $-10.26B | $9.48B | $4.42B | $-410.00M | $-11.85B | $-6.24B | $-91.00M |
| Accounts Receivables | $-1.24B | $-795.00M | $-2.65B | $2.21B | $245.00M | $-494.00M | $-2.90B | $1.68B | $371.00M | $-153.00M | $-4.52B | $317.00M | $1.64B | $40.00M | $-4.31B | $4.50B | $-2.77B | $-540.00M | $-6.16B | $3.69B |
| Inventory | $-407.00M | $618.00M | $-4.25B | $465.00M | $1.09B | $502.00M | $-955.00M | $-568.00M | $88.00M | $404.00M | $- | $- | $- | $- | $- | $-185.00M | $1.07B | $-441.00M | $- | $- |
| Accounts Payables | $-86.00M | $1.63B | $5.26B | $-19.00M | $-2.41B | $2.67B | $3.84B | $-454.00M | $1.71B | $-1.23B | $4.44B | $218.00M | $772.00M | $-3.64B | $4.26B | $-249.00M | $823.00M | $1.15B | $-231.00M | $267.00M |
| Other Working Capital | $489.00M | $70.00M | $-79.00M | $-217.00M | $164.00M | $410.00M | $-261.00M | $-262.00M | $192.00M | $21.00M | $-1.01B | $-518.00M | $10.54B | $-6.66B | $9.53B | $353.00M | $466.00M | $-12.02B | $9.00M | $-563.00M |
| Other Non Cash Items | $-54.00M | $75.00M | $45.00M | $79.00M | $-76.00M | $-100.00M | $-55.00M | $1.66B | $1.93B | $879.00M | $2.17B | $198.00M | $1.16B | $1.95B | $2.20B | $-69.00M | $91.00M | $-226.00M | $9.79B | $3.64B |
| Net Cash Provided by Operating Activities | $3.15B | $6.21B | $2.94B | $10.00B | $3.13B | $6.10B | $6.00B | $5.54B | $7.58B | $3.22B | $5.32B | $6.87B | $18.55B | $-4.53B | $16.33B | $11.03B | $6.90B | $-5.19B | $1.14B | $6.75B |
| Investments in Property Plant and Equipment | $-444.00M | $-650.00M | $-469.00M | $-451.00M | $-557.00M | $-574.00M | $-568.00M | $-562.00M | $-629.00M | $-695.00M | $-555.00M | $-657.00M | $-724.00M | $-866.00M | $-760.00M | $-829.00M | $-838.00M | $-959.00M | $-743.00M | $-853.00M |
| Acquisitions Net | $-3.45B | $-143.00M | $-929.00M | $-3.02B | $-374.00M | $-2.81B | $-1.19B | $-3.45B | $-85.00M | $-94.00M | $-1.23B | $-5.92B | $-4.00M | $-14.30B | $-7.83B | $-335.00M | $-228.00M | $-1.79B | $-3.01B | $-25.00M |
| Purchases of Investments | $-374.00M | $-476.00M | $-3.87B | $-2.55B | $5.03B | $-1.45B | $-4.61B | $-4.24B | $5.14B | $1.86B | $-1.63B | $-3.92B | $-701.00M | $-2.77B | $-2.32B | $3.32B | $6.38B | $-5.32B | $-4.80B | $-5.33B |
| Sales Maturities of Investments | $5.36B | $4.27B | $30.00M | $543.00M | $3.20B | $3.56B | $2.90B | $3.16B | $3.07B | $6.17B | $3.35B | $2.19B | $4.58B | $1.87B | $2.58B | $-2.58B | $-7.65B | $6.39B | $5.29B | $4.62B |
| Other Investing Activities | $-5.53B | $-4.39B | $3.70B | $2.52B | $-10.16B | $-3.90B | $-232.00M | $-416.00M | $-9.38B | $-6.53B | $-3.60B | $-277.00M | $-4.00B | $699.00M | $-2.69B | $-309.00M | $-297.00M | $-239.00M | $-3.08B | $-5.83B |
| Net Cash Used for Investing Activities | $-4.43B | $-1.39B | $-1.53B | $-2.95B | $-2.87B | $-5.18B | $-3.71B | $-5.50B | $-1.88B | $716.00M | $-3.67B | $-8.59B | $-847.00M | $-15.37B | $-11.02B | $-728.00M | $-2.64B | $-1.92B | $-6.34B | $-7.42B |
| Debt Repayment | $-2.23B | $-500.00M | $-10.24B | $- | $-1.50B | $-1.65B | $-1.15B | $-750.00M | $-1.30B | $-51.00M | $-1.10B | $-4.11B | $-1.02B | $-899.00M | $-1.38B | $-750.00M | $-411.00M | $-1.57B | $-11.36B | $-1.43B |
| Common Stock Issued | $292.00M | $297.00M | $557.00M | $313.00M | $336.00M | $234.00M | $436.00M | $328.00M | $313.00M | $278.00M | $551.00M | $205.00M | $328.00M | $169.00M | $344.00M | $284.00M | $411.00M | $314.00M | $486.00M | $258.00M |
| Common Stock Repurchased | $-600.00M | $-399.00M | $-1.69B | $- | $-850.00M | $-1.71B | $-1.65B | $-1.25B | $-1.05B | $-1.05B | $-2.50B | $-2.50B | $-1.00B | $-1.00B | $-2.00B | $-3.00B | $-1.50B | $-1.50B | $-3.07B | $-486.00M |
| Dividends Paid | $-1.02B | $-1.02B | $-1.02B | $-1.19B | $-1.19B | $-1.18B | $-1.18B | $-1.37B | $-1.37B | $-1.36B | $-1.36B | $-1.54B | $-1.54B | $-1.54B | $-1.54B | $-1.75B | $-1.74B | $-1.74B | $-1.73B | $-1.94B |
| Other Financing Activities | $3.50B | $-4.59B | $21.70B | $-5.40B | $-1.82B | $2.71B | $4.33B | $2.82B | $-992.00M | $-1.44B | $6.72B | $672.00M | $-186.00M | $7.66B | $17.76B | $-5.25B | $-3.87B | $-1.93B | $1.18B | $-945.00M |
| Net Cash Used Provided by Financing Activities | $-56.00M | $-6.21B | $9.30B | $-6.28B | $-5.02B | $-1.60B | $787.00M | $-218.00M | $-4.40B | $-3.63B | $2.30B | $946.00M | $-3.42B | $4.39B | $13.19B | $-10.46B | $-7.10B | $-6.43B | $8.23B | $-1.20B |
| Effect of Forex Changes on Cash | $-43.00M | $17.00M | $-129.00M | $-14.00M | $-17.00M | $44.00M | $-51.00M | $57.00M | $-51.00M | $-17.00M | $157.00M | $-100.00M | $-53.00M | $30.00M | $51.00M | $55.00M | $-57.00M | $48.00M | $-48.00M | $4.00M |
| Net Change in Cash | $-1.38B | $-1.38B | $10.58B | $758.00M | $-4.78B | $-629.00M | $3.03B | $-123.00M | $1.25B | $290.00M | $4.11B | $-870.00M | $14.23B | $-15.48B | $18.55B | $-100.00M | $-2.90B | $-13.49B | $2.99B | $-2.13B |
| Cash at End of Period | $12.36B | $10.98B | $21.57B | $22.33B | $17.55B | $16.92B | $19.95B | $19.83B | $21.09B | $21.38B | $25.48B | $24.61B | $38.84B | $23.36B | $41.91B | $41.81B | $38.91B | $25.43B | $28.41B | $26.29B |
| Cash at Beginning of Period | $13.74B | $12.36B | $10.98B | $21.57B | $22.33B | $17.55B | $16.92B | $19.95B | $19.83B | $21.09B | $21.38B | $25.48B | $24.61B | $38.84B | $23.36B | $41.91B | $41.81B | $38.91B | $25.43B | $28.41B |
| Operating Cash Flow | $3.15B | $6.21B | $2.94B | $10.00B | $3.13B | $6.10B | $6.00B | $5.54B | $7.58B | $3.22B | $5.32B | $6.87B | $18.55B | $-4.53B | $16.33B | $11.03B | $6.90B | $-5.19B | $1.14B | $6.75B |
| Capital Expenditure | $-444.00M | $-650.00M | $-469.00M | $-451.00M | $-557.00M | $-574.00M | $-568.00M | $-562.00M | $-629.00M | $-695.00M | $-555.00M | $-657.00M | $-724.00M | $-866.00M | $-760.00M | $-829.00M | $-838.00M | $-959.00M | $-743.00M | $-853.00M |
| Free Cash Flow | $2.71B | $5.55B | $2.47B | $9.55B | $2.57B | $5.53B | $5.44B | $4.98B | $6.95B | $2.52B | $4.76B | $6.21B | $17.82B | $-5.40B | $15.57B | $10.20B | $6.06B | $-6.15B | $401.00M | $5.89B |
UnitedHealth Group Dividends
Understand UnitedHealth Group's dividend history, dividend yield, payout ratio, and more.
Dividend Yield
1.38%
Dividend Payout Ratio
30.21%
Dividend Paid & Capex Coverage Ratio
8.61x
UnitedHealth Group Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $2.1 | $2.1 | September 16, 2024 | September 16, 2024 | September 24, 2024 | August 07, 2024 |
| $2.1 | $2.1 | June 17, 2024 | June 17, 2024 | June 25, 2024 | June 05, 2024 |
| $1.88 | $1.88 | March 08, 2024 | March 11, 2024 | March 19, 2024 | February 23, 2024 |
| $1.88 | $1.88 | December 01, 2023 | December 04, 2023 | December 12, 2023 | November 08, 2023 |
| $1.88 | $1.88 | September 08, 2023 | September 11, 2023 | September 19, 2023 | August 23, 2023 |
| $1.88 | $1.88 | June 15, 2023 | June 19, 2023 | June 27, 2023 | June 07, 2023 |
| $1.65 | $1.65 | March 10, 2023 | March 13, 2023 | March 21, 2023 | February 27, 2023 |
| $1.65 | $1.65 | December 02, 2022 | December 05, 2022 | December 13, 2022 | November 04, 2022 |
| $1.65 | $1.65 | September 09, 2022 | September 12, 2022 | September 20, 2022 | August 17, 2022 |
| $1.65 | $1.65 | June 16, 2022 | June 20, 2022 | June 28, 2022 | June 08, 2022 |
| $1.45 | $1.45 | March 11, 2022 | March 14, 2022 | March 22, 2022 | February 16, 2022 |
| $1.45 | $1.45 | December 03, 2021 | December 06, 2021 | December 14, 2021 | November 05, 2021 |
| $1.45 | $1.45 | September 10, 2021 | September 13, 2021 | September 21, 2021 | August 11, 2021 |
| $1.45 | $1.45 | June 18, 2021 | June 21, 2021 | June 29, 2021 | June 09, 2021 |
| $1.25 | $1.25 | March 12, 2021 | March 15, 2021 | March 23, 2021 | February 24, 2021 |
| $1.25 | $1.25 | December 04, 2020 | December 07, 2020 | December 15, 2020 | November 04, 2020 |
| $1.25 | $1.25 | September 11, 2020 | September 14, 2020 | September 22, 2020 | August 05, 2020 |
| $1.25 | $1.25 | June 19, 2020 | June 22, 2020 | June 30, 2020 | June 02, 2020 |
| $1.08 | $1.08 | March 13, 2020 | March 16, 2020 | March 24, 2020 | February 17, 2020 |
| $1.08 | $1.08 | December 06, 2019 | December 09, 2019 | December 17, 2019 | November 08, 2019 |
Valuation
Analyze the market cap, enterprise value, and valuation metrics for UnitedHealth Group.
Market Cap & Enterprise Value
Market Cap: $536.18B
Enterprise Value: $530.57B
Valuation Ratios
P/E Ratio: 21.83
P/B Ratio: 5.50
P/CF Ratio: 16.81
Valuation Multiples
E/V to Sales: 1.44
E/V to EBITDA: 16.46
Market Cap & Enterprise Value
Market capitalization and enterprise value provide an understanding of a company's market value and total value, respectively.
- Market Cap: The total market value of a company's outstanding shares of stock. It represents the company's equity value and is calculated by multiplying the current share price by the total number of outstanding shares.
- Enterprise Value (EV): A measure of a company's total value, often seen as a more comprehensive alternative to equity market capitalization. It includes market cap plus debt, minority interest, and preferred shares, minus total cash and cash equivalents.
Valuation Ratios
Valuation ratios are used to evaluate the value of a company compared to its earnings, book value, and cash flow.
- P/E Ratio: Price to Earnings Ratio, indicating how much investors are willing to pay for a dollar of earnings.
- P/B Ratio: Price to Book Ratio, comparing the company's market value to its book value. A lower ratio may indicate undervaluation.
- P/CF Ratio: Price to Cash Flow Ratio, evaluating the market value relative to the operating cash flow. A lower ratio can signal a more attractive investment.
Valuation Multiples
Valuation multiples help assess a company's value relative to its revenue and earnings.
- EV to Sales: Enterprise Value to Sales, comparing the enterprise value to sales revenue. A lower ratio can indicate a more attractive investment.
- EV to EBITDA: Enterprise Value to EBITDA, comparing the enterprise value to earnings before interest, taxes, depreciation, and amortization. A lower ratio suggests a company may be undervalued.
UnitedHealth Group Growth
View income_statement_chart2_annual_data financial growth metrics for UnitedHealth Group, including income statement, balance sheet, and cash flow growth.
Income Growth
Revenue Growth: -0.94%
Operating Income Growth: -0.71%
Cash Flow Growth
Net Income Growth: 399.22%
Free Cash Flow Growth: 1369.58%
Balance Sheet Growth
Total Assets Growth: 0.65%
Total Liabilities Growth: -0.25%
Income Growth
This section highlights key metrics related to income growth, showing how the company’s revenue and operating income have changed over time:
- Revenue Growth: The increase in a company's sales over time. It is a measure of how quickly the company is growing its revenue. This chart shows the historical trend of revenue growth.
- Operating Income Growth: The growth rate of a company's operating income, which is the income earned from its normal business operations. This chart helps to assess the company's operational efficiency and profitability growth over time.
Cash Flow Growth
This section highlights key metrics on the company's cash flow growth, reflecting changes in net income and free cash flow over time.
- Net Income Growth: The increase in a company's net profit over time. It reflects the company's ability to increase its profitability. This chart provides insight into how the company's bottom line has grown.
- Free Cash Flow Growth: The growth in a company's free cash flow, which is the cash generated by the company after accounting for capital expenditures. This chart is important for understanding the company's financial flexibility and ability to fund operations and growth.
Balance Sheet Growth
This section highlight key metrics related to balance sheet growth, which indicate how the company’s total assets and liabilities have changed over time:
- Total Assets Growth: The rate at which a company's total assets are increasing over time. This chart indicates how the company's asset base is expanding, which can be a sign of growth and investment in future operations.
- Total Liabilities Growth: The rate at which a company's total liabilities are increasing over time. This chart helps to assess the company's financial leverage and risk over time.
Peers: Medical - Healthcare Plans
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
Cigna Corporation
CI
|
$99.35B | $355.39 | $17.57 | $17.04 | $1.90 |
Humana Inc.
HUM
|
$37.96B | $315.29 | $20.09 | $22.78 | $3.49 |
Elevance Health Inc.
ELV
|
$125.09B | $539.46 | $25.38 | $18.58 | $2.83 |
Centene Corporation
CNC
|
$40.15B | $76.32 | $4.97 | $14.92 | $1.56 |
Molina Healthcare, Inc.
MOH
|
$20.81B | $355.15 | $18.91 | $19.11 | $4.95 |
CVS Health Corporation
CVS
|
$73.49B | $58.42 | $6.49 | $12.16 | $1.33 |
Alignment Healthcare, Inc.
ALHC
|
$2.18B | $11.38 | $-0.79 | $-10.83 | $10.22 |
More metrics for UnitedHealth Group
Access more key metrics, financials, ratios, and more with the links below.